

Revisions of Consolidated Financial Forecasts

ONO PHARMACEUTICAL CO., LTD. (Osaka, Japan; President, Representative Director and CEO: Gyo Sagara) announced today that it has revised its 2nd quarter consolidated financial forecasts for the fiscal year ending March 31, 2018, which were announced on May 11, 2017, in light of recent business trends.

1. Revisions to 2nd Quarter Consolidated Financial Forecasts for the Fiscal Year Ending March 31, 2018 (April 1, 2017 – September 30, 2017)

(Millions of yen, except Basic earnings per share)

	Revenue	Operating profit	Profit before tax	Profit (Owners of the Parent Company)	Basic earnings per share (yen)
Previous Forecast (A)	112,500	13,200	14,500	10,700	20.19
Revised Forecast (B)	121,000	26,700	28,300	21,200	40.61
Change (B – A)	8,500	13,500	13,800	10,500	-
Change (%)	7.6%	102.3%	95.2%	98.1%	-
(Reference) Results of the previous corresponding period	117,726	30,135	31,127	23,119	43.62

2. Reasons for Revisions

The revenue is forecasted to be ¥121.0 billion, an increase of ¥8.5 billion from the previous forecast. The royalty income of OPDIVO[®] Intravenous Infusion mainly from Bristol-Myers Squibb Company is expected to exceed the previous forecasts. In addition, the sales of OPDIVO are also expected to exceed the previous forecasts although the sales of OPDIVO will be significantly decreased due to the influence of drug price cut executed in February 2017.

With respect to profit, Operating profit is forecasted to increase by ¥13.5 billion to ¥26.7 billion, Profit before tax will increase by ¥13.8 billion to 28.3 billion, Profit for the period attributable to owners of the parent company is expected to grow by ¥10.5 billion to ¥21.2 billion, from the respective previous forecasts. This revision is made because

parts of Research and development costs and Selling, general and administrative expenses expected in the 2nd quarter cumulative period will be incurred to the 3rd quarter and thereafter.

We are now scrutinizing its full year forecast and it will be presented at the time of the six months ending results announcement on November 6, 2017.

(Note) The above financial forecasts and statements contained in this announcement are made based on information available as of the announcement date. Actual results may differ materially from those set forth in the announcements due to various uncertain factors

Contact

ONO PHARMACEUTICAL CO., LTD.

Corporate Communications

public_relations@ono.co.jp